What's the future of telehealth as we emerge out of the pandemic? This guest contributor weighs in. Photo via Getty Images

As medical practitioners were faced with the abrupt arrival of the pandemic, they had to immediately adapt to new technologies and switch to telehealth – fundamentally changing the way healthcare is delivered. During the first few months of the pandemic, many private practices were forced to close their doors. Some have since opened with limited schedules, but many are still feeling the effects linger.

Telehealth has grown in popularity due to the efficiency and convenience it offers to both patients and providers. A recent CDC report noted that 30 percent of weekly health care visits occurred via telehealth from June to November 2020. According to the Health Center Program Data, 43 percent of health centers were capable of providing telehealth in 2019, compared to 95 percent of health centers using telehealth during the COVID-19 pandemic.

As patients and healthcare institutions navigate this remote landscape, many challenges need to be addressed. Particularly, the rules and regulations that govern telehealth and how to ensure telehealth platforms can be used safely to offer care. Beyond policies and laws, there are several infrastructure hurdles affecting the implementation of telehealth services in rural areas, making this population vulnerable to inadequate access to care. The same CDC report noted that rural areas reported the lowest average of weekly health care visits via telehealth.

Practitioners also face new challenges evaluating and diagnosing patients without having the ability to do a hands-on physical exam and access to vitals such as blood pressure, heart rate and temperature during virtual visits. Telehealth visits are no match for direct, inpatient clinical visits, but practitioners are still trying to find its role in our current healthcare system.

Some of the ways we've integrated a technology-driven approach to healthcare at WellnessSpace is through putting together the best of both worlds. We focus on in-person visits that have the convenience of technology to enhance the experience of both members and their clients. We use client self-check-in kiosks, an interactive mobile app that allows our members to reserve suites on-demand, download invoices, manage their bios and message other members. We are focusing on providing an easy and integrated experience for both patients and practitioners, which is something that will play a key role in how practitioners and patients navigate the "new normal" as we move forward.

We can expect telehealth to continue to play a vital role in providing healthcare, but for the vast majority of practices, telehealth will supplement in-person visits, not replace them. In a release from the Department of Health and Human Services, surveyed practitioners expect telehealth to remain at 21 percent compared to 51 percent during the pandemic.

Overall, the pandemic has opened the doors for telehealth and increased its adoption among all age groups. It's provided an alternative for practitioners to still offer care, just in a different way. While it's not ideal for all situations, this technology is a tool that can help practitioners continue what they do best – helping patients.

------

Sunny Somaiya is the co-owner of Houston-based WellnessSpace.

Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

Axiom Space-tested cancer drug advances to clinical trials

mission critical

A cancer-fighting drug tested aboard several Axiom Space missions is moving forward to clinical trials.

Rebecsinib, which targets a cancer cloning and immune evasion gene, ADAR1, has received FDA approval to enter clinical trials under active Investigational New Drug (IND) status, according to a news release. The drug was tested aboard Axiom Mission 2 (Ax-2) and Axiom Mission 3 (Ax-3). It was developed by Aspera Biomedicine, led by Dr. Catriona Jamieson, director of the UC San Diego Sanford Stem Cell Institute (SSCI).

The San Diego-based Aspera team and Houston-based Axiom partnered to allow Rebecsinib to be tested in microgravity. Tumors have been shown to grow more rapidly in microgravity and even mimic how aggressive cancers can develop in patients.

“In terms of tumor growth, we see a doubling in growth of these little mini-tumors in just 10 days,” Jamieson explained in the release.

Rebecsinib took part in the patient-derived tumor organoid testing aboard the International Space Station. Similar testing is planned to continue on Axiom Station, the company's commercial space station that's currently under development.

Additionally, the drug will be tested aboard Ax-4 under its active IND status, which was targeted to launch June 25.

“We anticipate that this monumental mission will inform the expanded development of the first ADAR1 inhibitory cancer stem cell targeting drug for a broad array of cancers," Jamieson added.

According to Axiom, the milestone represents the potential for commercial space collaborations.

“We’re proud to work with Aspera Biomedicines and the UC San Diego Sanford Stem Cell Institute, as together we have achieved a historic milestone, and we’re even more excited for what’s to come,” Tejpaul Bhatia, the new CEO of Axiom Space, said in the release. “This is how we crack the code of the space economy – uniting public and private partners to turn microgravity into a launchpad for breakthroughs.”